Abstract

The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor ("CRF receptor")

5

$$\begin{array}{c|c}
R^{2} & R^{3} \\
\hline
R^{2} & B \\
\hline
SO_{2} & (I) \\
\hline
R^{1} & N & D \\
Ar
\end{array}$$

useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.